RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
  Brain Diseases
  Demyelinating Diseases
   Multiple Sclerosis
  Headache
  Memory
  Neurochemistry
  Neurodegenerative Diseases
  Regeneration
  Spinal Cord Diseases
  Stroke
  Taste
  Trigeminal Neuralgia
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Multiple Sclerosis Channel

subscribe to Multiple Sclerosis newsletter
Latest Research : Neurosciences : Demyelinating Diseases : Multiple Sclerosis

   EMAIL   |   PRINT
Interferon Does Not Affect Duration Of "Black Hole" Lesions In Multiple Sclerosis

Sep 13, 2005 - 1:57:00 PM
"One can postulate that although IFNβ-1b may reduce the frequency of BHs, after the lesion occurs, the drug is not changing the pathological process"

 
[RxPG] Although treatment with interferon appears to reduce the formation of new areas of damage in the brains of patients with multiple sclerosis (MS), including lesions that appear as highly contrasted images, called black holes, on magnetic resonance imaging (MRI), treatment does not appear to affect the duration of these damaged regions, according to a new study posted online today by the Archives of Neurology, one of the JAMA/Archives journals. The study will be published in the November print edition of the journal.

Previous studies have shown that treatment with interferon beta-1b, a chemical that has activity on the immune system, reduces the formation of lesions visible to MRI, according to background information in the article. Chronic, persisting black holes reflect areas of irreversible nerve fiber loss and permanent damage. Black holes of shorter duration are believed to reflect the presence of short-term swelling. Shortening the duration of black holes, the authors suggest, may prevent the formation of permanent detrimental lesions, ultimately exerting a neuro-protective effect.

Francesca Bagnato, M.D., of the National Institute of Neurological Disorders and Stroke, Bethesda, Md., and colleagues analyzed MRIs for both the formation and duration of black holes for six patients with relapsing-remitting type MS. Monthly MRIs were obtained for 36 months before the treatment was initiated (natural history phase) and for 36 months during treatment with interferon (therapy phase).

The researchers found that the number of new black holes increased during both the treatment and natural history phases for all patients, but the accumulation of new black holes was substantially lower for patients during the treatment phase. The duration of new black holes arising during the treatment phase was not shorter than the duration of black holes arising during the natural history phase, however.

"The sample size is small, but the length of the longitudinal followup (i.e., 72 months) represents a robust and valid data set for describing the course of MS during both the NHPs [natural history phase] and TPs [therapy phase]," the authors note. "We demonstrate that new BHs [black holes] may significantly accumulate over time even when IFNβ-1b [interferon beta-1b] is administered. However, repeated administration of the drug did significantly decrease the rate of BH formation, thus protecting the brain tissue from accumulating degenerative lesions."

"One can postulate that although IFNβ-1b may reduce the frequency of BHs, after the lesion occurs, the drug is not changing the pathological process," the authors write. They suggest larger studies over longer periods might reduce difficulties in interpretation encountered in this study, allowing a better assessment of whether the analysis used might be useful in establishing the proper role of neuroprotective drugs of the central nervous system in the treatment of patients with MS.



Publication: Archives of Neurology (online edition)
On the web: Arch Neurol. 2005;62:1-5 

Advertise in this space for $10 per month. Contact us today.


Related Multiple Sclerosis News
Smoking associated with rapid progression of multiple sclerosis
Testosterone may help men with multiple sclerosis
Age of onset but not severity of Multiple Sclerosis inherited from parents
Cause of nerve fiber damage in multiple sclerosis identified
Fampridine may hold promise for treating Multiple Sclerosis
CNS can send out signals to invite autoimmune attacks
Natalizumab Re-approved for Relapsing Multiple Sclerosis
Efficacy in relapse rate reduction beyond five years shown for interferon beta 1b in Multiple Sclerosis
Systematic Review Questions Accuracy of MRI in Multiple Sclerosis
Statins could prove useful in treating MS

Subscribe to Multiple Sclerosis Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)